Infections caused by methicillin-resistant Staphylococcus aureus are becoming increasingly prevalent. Vancomycin alone or associated with aminoglycosides is the most effective therapy available for treating these infections, but because of the potential toxicity of these drugs, new alternative antibiotic regimens are required. Fosfomycin is an antibiotic with no reported toxicity which is active in vitro and in vivo against gram-negative and gram-positive microorganisms (10), including both methicillin-susceptible and methicillin-resistant strains of S. aureus (1, 3, 8) .
In a previous paper (6), we reported the efficacy of fosfomycin in the treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. The aim of the present study was to evaluate the efficacy of the combinations of fosfomycin with vancomycin and fosfomycin with gentamicin in the treatment of experimental rabbit endocarditis caused by methicillin-resistant S. aureus to assess the potential clinical usefulness of these combinations in therapy for serious infections caused by methicillinresistant S. aureus.
( Surviving rabbits were killed 18 h after the last dose. The vegetations were removed, weighed, and homogenized, and the titers were determined by 10-fold serial dilutions. Vegetations were considered sterile when no growth was seen after undiluted tissue vegetations were subcultured. Animals that died during therapy were included only if they were autopsied within 6 h of death. Student's t test and the Fisher exact test were used for the comparison of differences between log10 CFU per gram of vegetations and differences between proportions of the various groups of animals, respectively. For multiple comparisons, the Bonferroni correction was used.
The results are shown in Table 1 . The mortality rate of untreated controls was 85.7%, with deaths occurring between days 3 and 7 after infection. Mortality decreased significantly in the groups treated with fosfomycin (P s 0.01) and vancomycin (P s 0.005). Animals receiving fosfomycin died after 4 or 5 days of therapy. One death occurred after 2 days of therapy in the vancomycin group. No animals died in the groups treated with the combinations. In the control group, all rabbits had infected vegetations. Therapy with either fosfomycin or vancomycin significantly reduced bacterial titers of vegetations (P s 0.01) compared with those of the controls. No increase in the MIC of fosfomycin or vancomycin was found in colonies of the vegetations of any group. The rate of sterilization in the groups treated with fosfomycin-vancomycin and fosfomycin-gentamicin was 100%, which was significantly higher than that of fosfomycin alone (P c 0.01) but not significantly different from that of vancomycin alone (P > 0.01).
Our results indicate that fosfomycin alone was comparable to vancomycin in reducing bacterial counts of vegetations.
Moreover, fosfomycin-vancomycin and fosfomycin-gentamicin were highly effective, since all rabbits had sterile vegetations. These in vivo results have a good correlation with the in vitro time-kill studies reported above and suggest that fosfomycin is a useful alternative in the therapy of methicillin-resistant S. aureus infections when given in combination with vancomycin or gentamicin, but further studies are necessary to confirm these results.
